Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Bar Code Label Requirement for Human Drug and Biological Products, 28856-28857 [2013-11630]
Download as PDF
28856
Federal Register / Vol. 78, No. 95 / Thursday, May 16, 2013 / Notices
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1—Continued
Number of
recordkeepers
Total ..............................................................................
1 There
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
........................
21 CFR Section
........................
........................
........................
Total hours
29,000
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 3—ESTIMATED ANNUAL THIRD PARTY DISCLOSURE BURDEN 1
§§ 107.10(a) and 107.20 ......................................................
tkelley on DSK3SPTVN1PROD with NOTICES
1 There
Number of
disclosures
per
respondent
Number of
respondents
21 CFR Section
5
Total annual
disclosures
13
65
Average
burden per
disclosure
Total hours
8
520
are no capital costs or operating and maintenance costs associated with this collection of information.
In compiling these estimates, we
consulted our records of the number of
infant formula submissions received in
the past. All infant formula submissions
may be provided to us in electronic
format. The hours per response
reporting estimates are based on our
experience with similar programs and
information received from industry.
We estimate that we will receive 13
reports from 5 manufacturers annually
under section 412(d) of the FD&C Act,
for a total annual response of 65 reports.
Each report is estimated to take 10 hours
per response for a total of 650 hours. We
also estimate that we will receive one
notification under § 106.120(b). The
notification is expected to take 4 hours
per response, for a total of 4 hours.
For exempt infant formula, we
estimate that we will receive two reports
from three manufacturers annually
under §§ 107.50(b)(3) and (b)(4), for a
total annual response of six reports.
Each report is estimated to take 4 hours
per response for a total of 24 hours. We
also estimate that we will receive one
notification annually under
§ 107.50(e)(2) and that the notification
will take 4 hours to prepare.
We estimate that 5 firms will expend
approximately 20,000 hours per year to
fully satisfy the recordkeeping
requirements in § 106.100 and that 3
firms will expend approximately 9,000
hours per year to fully satisfy the
recordkeeping requirements in
§ 107.50(c)(3).
We estimate compliance with our
labeling requirements in §§ 107.10(a)
and 107.20 requires 520 hours annually
by 5 manufacturers.
Dated: May 9, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–11631 Filed 5–15–13; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
18:13 May 15, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
collection of information to OMB for
review and clearance.
Food and Drug Administration
Bar Code Label Requirement for
Human Drug and Biological Products—
(OMB Control Number 0910–0537)—
Extension
[Docket No. FDA–2012–N–0873]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Bar Code Label
Requirement for Human Drug and
Biological Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by June 17,
2013.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0537. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
7726, Ila.Mizrachi@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
SUMMARY:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
In the Federal Register of February
26, 2004 (69 FR 9120), we issued
regulations that required human drug
product and biological product labels to
have bar codes. The rule required bar
codes on most human prescription drug
products and on over-the-counter (OTC)
drug products that are dispensed under
an order and commonly used in health
care facilities. The rule also required
machine-readable information on blood
and blood components. For human
prescription drug products and OTC
drug products that are dispensed under
an order and commonly used in health
care facilities, the bar code must contain
the National Drug Code number for the
product. For blood and blood
components, the rule specifies the
minimum contents of the machinereadable information in a format
approved by the Center for Biologics
Evaluation and Research Director as
blood centers have generally agreed
upon the information to be encoded on
the label. The rule is intended to help
reduce the number of medication errors
in hospitals and other health care
settings by allowing health care
professionals to use bar code scanning
equipment to verify that the right drug
(in the right dose and right route of
administration) is being given to the
right patient at the right time.
Most of the information collection
burden resulting from the final rule, as
calculated in table 1 of the final rule (69
FR 9120 at 9149), was a one-time
burden that does not occur after the
rule’s compliance date of April 26,
2006. In addition, some of the
information collection burden estimated
E:\FR\FM\16MYN1.SGM
16MYN1
28857
Federal Register / Vol. 78, No. 95 / Thursday, May 16, 2013 / Notices
in the final rule is now covered in other
OMB-approved information collection
packages for FDA. However, parties may
continue to seek an exemption from the
bar code requirement under certain,
limited circumstances. Section
201.25(d) (21 CFR 201.25(d)) requires
submission of a written request for an
exemption and describes the contents of
such requests. Based on the number of
exemption requests we have received,
we estimate that approximately 2
exemption requests may be submitted
annually, and that each exemption
request will require 24 hours to
complete. This would result in an
annual reporting burden of 48 hours.
In the Federal Register of August 17,
2012 (77 FR 49818), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden for this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 CFR Section
§ 201.25(d) .................................................................
1 There
[FR Doc. 2013–11630 Filed 5–15–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
HHS.
ACTION:
Notice
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
tkelley on DSK3SPTVN1PROD with NOTICES
Total annual
responses
1
2
2
Average burden
per response
24
Total hours
48
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: May 10, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
AGENCY:
Number of
responses per
respondent
A Diagnostic Kit for Assessing Exposure
or Infection by the Koala Family of
Retroviruses
Description of Technology: Inventors
at the NIH have discovered a new family
VerDate Mar<15>2010
18:13 May 15, 2013
Jkt 229001
of infectious koala retroviruses that are
correlated with the development of
malignant neoplasias, including
lymphomas and leukemias. This
invention relates to a diagnostic kit for
assessing exposure or infection by a
koala retrovirus. The kit consists of
specific primers and probes for the
detection of three distinct subtypes of
infectious koala retrovirus and may be
useful in various species, including
humans, primates, and koalas.
Infectious koala retroviruses have been
shown to infect human cells in culture,
though the health implications in
humans have not yet been fully
determined.
Potential Commercial Applications:
• A diagnostic kit for assessing
exposure or infection by the koala
family of retroviruses
• May be useful in monitoring
effectiveness of antiretroviral treatment
Competitive Advantages: Detection of
newly discovered subtypes of infectious
koala retroviruses.
Development Stage:
• Early-stage
• In vitro data available
Inventors: Maribeth V. Eiden (NIMH),
Wenqin Xu (NIMH), William M. Switzer
(CDC), HaoQiang Zheng (CDC)
Intellectual Property: HHS Reference
No. E–053–2013/0—US Application No.
61/784,763 filed 14 Mar 2013
Licensing Contact: Charlene Sydnor,
Ph.D.; 301–435–4689;
sydnorc@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Mental Health
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize A
Diagnostic Kit for Assessing Exposure or
Infection by the Koala Family of
Retroviruses. For collaboration
opportunities, please contact Suzanne L.
Winfield, Ph.D. at winfiels@mail.nih.gov
or 301–402–4324.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Retroviral Vector Packaging Cell Lines
and Purification Methods for Gene
Therapy
Description of Technology: This
invention relates to a novel
gammaretroviral vector packaging cell
line and method of producing
gammaretroviral vectors suitable for
gene therapy. The described vectors
may contain the gibbon ape leukemia
virus (GALV) envelope with a CD11D8
epitope tag enabling their purification
on a monoclonal antibody conjugated
column. These vectors have several
advantages over existing systems,
including a broader host range, higher
infectivity, and lower potential for
replication. Further, purification of
retroviral vector particles via an epitope
tag may remove cellular components
and debris toxic to target cells and
tissues, providing a safer method of
delivery for patients receiving gene
therapy.
Potential Commercial Applications:
Retroviral vector particles for gene
therapy.
Competitive Advantages:
• Broader host range
• Higher infectivity
• Lower potential for replication
• Decreased toxicity after purification
Development Stage:
• Early-stage
• In vitro data available
Inventors: Maribeth V. Eiden and
Wenqin Xu (NIMH)
Intellectual Property: HHS Reference
No. E–036–2013/0—US Application No.
61/759,516 filed 01 Feb 2013
Licensing Contact: Charlene Sydnor,
Ph.D.; 301–435–4689;
sydnorc@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Mental Health
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
E:\FR\FM\16MYN1.SGM
16MYN1
Agencies
[Federal Register Volume 78, Number 95 (Thursday, May 16, 2013)]
[Notices]
[Pages 28856-28857]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-11630]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0873]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Bar Code Label
Requirement for Human Drug and Biological Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by June
17, 2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0537.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-7726, Ila.Mizrachi@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Bar Code Label Requirement for Human Drug and Biological Products--(OMB
Control Number 0910-0537)--Extension
In the Federal Register of February 26, 2004 (69 FR 9120), we
issued regulations that required human drug product and biological
product labels to have bar codes. The rule required bar codes on most
human prescription drug products and on over-the-counter (OTC) drug
products that are dispensed under an order and commonly used in health
care facilities. The rule also required machine-readable information on
blood and blood components. For human prescription drug products and
OTC drug products that are dispensed under an order and commonly used
in health care facilities, the bar code must contain the National Drug
Code number for the product. For blood and blood components, the rule
specifies the minimum contents of the machine-readable information in a
format approved by the Center for Biologics Evaluation and Research
Director as blood centers have generally agreed upon the information to
be encoded on the label. The rule is intended to help reduce the number
of medication errors in hospitals and other health care settings by
allowing health care professionals to use bar code scanning equipment
to verify that the right drug (in the right dose and right route of
administration) is being given to the right patient at the right time.
Most of the information collection burden resulting from the final
rule, as calculated in table 1 of the final rule (69 FR 9120 at 9149),
was a one-time burden that does not occur after the rule's compliance
date of April 26, 2006. In addition, some of the information collection
burden estimated
[[Page 28857]]
in the final rule is now covered in other OMB-approved information
collection packages for FDA. However, parties may continue to seek an
exemption from the bar code requirement under certain, limited
circumstances. Section 201.25(d) (21 CFR 201.25(d)) requires submission
of a written request for an exemption and describes the contents of
such requests. Based on the number of exemption requests we have
received, we estimate that approximately 2 exemption requests may be
submitted annually, and that each exemption request will require 24
hours to complete. This would result in an annual reporting burden of
48 hours.
In the Federal Register of August 17, 2012 (77 FR 49818), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden for this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Sec. 201.25(d)................................................... 2 1 2 24 48
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: May 10, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-11630 Filed 5-15-13; 8:45 am]
BILLING CODE 4160-01-P